

Table Title	Table Subject ion	Indication	Treatment	Rating Panelist 1	Rating Panelist 2	Rating Panelist 3	Rating Panelist 4	Rating Panelist 5	Rating Panelist 6	Rating Panelist 7	Rating Panelist 8	Rating Panelist 9	Rating Panelist 10	Rating Panelist 11	Rating Panelist 12	Rating Panelist 13	Rating Panelist 14	Rating Panelist 15	Rating Panelist 16	Rating Panelist 17	Median	AUC Rating	
Table 1: Asymptomatic, High Gradient, Severe AS		1. LVEF ≥50% Vmax 4 to 4.9 m/sec Negative exercise stress test No predictors of rapid progression / symptom onset / adverse events (e.g., ΔVmax >0.3 m/s/yr, severe valve calcification, elevated BNP, or excessive LV hypertrophy in the absence of hypertension) High or intermediate surgical risk	No Intervention	7	4	7	7	7	5	7	9	6	6	7	7	4	8	7	7	7	7	7	A
			AVR (TAVR or SAVR)	4	6	4	4	5	5	5	3	6	6	4	5	6	3	5	4	5	5	5	M

		5. • LVEF ≥50%• Vmax 4 to 4.9 m/sec• Negative exercise stress test• One or more predictors of rapid progression / symptom onset / adverse events(e.g., ΔVmax >0.3 m/s/yr, severe valve calcification, elevated BNP, or excessive LV hypertrophy in the absence of hypertension)• Low surgical risk	No Intervention	3	3	4	5	5	4	4	7	4	2	4	4	4	4	5	3	3	4	M	
			AVR (TAVR or SAVR)	8	7	6	6	6	7	8	5	7	8	8	8	6	8	8	8	8	8	8	A
		6. • LVEF ≥50%• Vmax 4 to 4.9 m/sec• Abnormal exercise stress test• High or intermediate surgical risk	No Intervention	1	1	2	6	2	3	3	3	3	2	3	3	2	3	2	3	3	3	3	R
			AVR (TAVR or SAVR)	9	9	8	7	8	8	8	8	8	9	8	8	8	8	8	8	8	7	8	A
		7. • LVEF ≥50%• Vmax 4 to 4.9 m/sec• Abnormal exercise stress test• Low surgical risk	No Intervention	1	1	4	5	4	3	2	1	2	2	2	3	4	2	3	2	2	2	2	R
			AVR (TAVR or SAVR)	9	9	7	8	7	8	8	8	8	9	8	8	8	8	8	8	8	7	8	A

		8. • LVEF ≥50%• Very severe AS (Vmax ≥5 m/sec or mean gradient ≥60 mmHg)• High or intermediate surgical risk	No Intervention	5	1	2	6	2	2	4	5	4	1	4	6	2	4	3	4	1	4	M
			AVR (TAVR or SAVR)	6	9	8	7	8	8	7	7	7	9	7	7	8	7	8	7	9	7	A
		9. • LVEF ≥50%• Very severe AS (Vmax ≥5 m/sec or mean gradient ≥60 mmHg)• Low surgical risk	No Intervention	5	1	2	5	2	2	2	4	2	2	2	4	2	2	2	2	1	2	R
			AVR (TAVR or SAVR)	6	9	8	7	8	8	8	8	8	7	8	8	8	8	8	8	9	8	A
		10. • LVEF <50%• Vmax ≥4 m/sec or mean gradient ≥40 mmHg• High or intermediate surgical risk	No Intervention	1	1	1	3	1	1	2	2	2	1	2	2	2	2	2	2	4	2	R
			AVR (TAVR or SAVR)	9	9	9	7	9	9	8	8	8	9	8	8	8	8	9	8	5	8	A
		11. • LVEF <50%• Vmax ≥4 m/sec or mean gradient ≥40 mmHg• Low surgical risk	No Intervention	1	1	1	2	1	1	1	1	8	1	1	2	2	1	2	1	6	1	R
			AVR (TAVR or SAVR)	9	9	9	8	9	9	9	9	1	9	9	8	9	9	9	9	6	9	A

		12. • Undergoing another cardiac surgery or ascending aortic surgery	No Intervention	1	3	2	1	1	2	1	1	1	1	1	1	1	1	2	1	1	1	R
			AVR (TAVR or SAVR)	9	6	8	9	9	4	9	9	9	9	9	9	9	9	9	9	9	9	A
Table 2: Flow, Gradient, and Ejection Fraction	Reduced Ejection Fraction ($<50\%$)	13. • AVA ≤ 1.0 cm ² (or indexed AVA ≤ 0.6 cm ² /m ²) on resting echo • LVEF 20 to $<50\%$ • Low flow • Low gradient • Flow reserve on low dose dobutamine echo • Truly severe AS • High or intermediate surgical risk	No Intervention	1	2	1	5	1	1	2	2	2	2	2	4	1	2	2	2	2	2	R
			BAV (bridge to decision)	4	7	2	5	1	1	3	4	5	2	2	2	3	4	2	4	5	3	R
			AVR (TAVR or SAVR)	9	8	9	5	8	8	8	8	8	8	8	8	9	8	8	8	7	8	A

		17. • AVA ≤1.0 cm ² (or indexed AVA ≤0.6 cm ² /m ²) on resting echo• LVEF 20 to <50%• Low flow• Low gradient• No flow reserve on low dose dobutamine echo• Minimal calcification on aortic valve on echo and/or CT• High or intermediate surgical risk	No Intervention	7	7	3	8	7	3	7	7	4	3	8	6	7	8	3	7	8	7	A
			BAV (bridge to decision)	3	4	5	4	1	5	2	3	5	4	3	3	4	2	3	3	3	3	R
			AVR (TAVR or SAVR)	2	2	8	4	1	8	2	2	7	7	2	6	4	2	7	2	1	2	R
		18. • AVA ≤1.0 cm ² (or indexed AVA ≤0.6 cm ² /m ²)• LVEF <20%• Vmax ≥4 m/sec or mean gradient ≥40 mmHg on resting echo• High or intermediate surgical risk	No Intervention	1	1	7	5	1	7	3	3	1	7	3	1	4	3	5	3	3	3	R
			BAV (bridge to decision)	4	5	1	4	1	3	5	5	2	3	5	4	8	4	5	5	5	4	M
			AVR (TAVR or SAVR)	8	8	2	7	9	3	7	7	8	2	7	8	7	7	7	7	8	7	A

		19. • AVA ≤1.0 cm2 (or indexed AVA ≤0.6 cm2/m2)• LVEF <20%• Mean gradient <20 mmHg on resting echo• No flow reserve on low dose dobutamine echo• High or intermediate surgical risk	No Intervention	5	9	8	8	9	8	6	6	7	7	7	4	6	6	7	6	8	7	A
			BAV (bridge to decision)	4	4	2	5	1	3	4	4	3	3	4	4	4	4	3	4	4	4	M
			AVR (TAVR or SAVR)	6	2	3	4	1	3	3	3	2	3	3	6	3	3	2	3	1	3	R
		20. • AVA ≤1.0 cm2 (or indexed AVA ≤0.6 cm2/m2) on resting echo• LVEF <20%• Low flow• Low gradient• Flow reserve on low dose dobutamine echo• Truly severe AS• High or intermediate surgical risk	No Intervention	2	2	3	7	1	3	3	3	3	3	4	3	4	3	4	3	3	3	R
			BAV (bridge to decision)	4	7	5	5	1	4	5	5	5	5	5	3	7	5	5	5	4	5	M
			AVR (TAVR or SAVR)	8	8	7	5	7	8	7	7	7	7	7	7	6	7	7	7	7	7	A

		25. • AVA ≤1.0 cm ² (and indexed AVA ≤0.6 cm ² /m ²)• Low flow• Low gradient• Symptomatic• Evidence of a severely calcified valve• Clinical, hemodynamic, and anatomic data support valve obstruction as the most likely cause of symptoms• Low surgical risk	No Intervention	2	1	1	3	1	1	1	1	1	1	1	2	3	1	1	1	2	1	R
			BAV (bridge to decision)	4	4	1	4	1	2	1	1	1	1	1	2	6	1	2	1	4	1	R
			AVR (TAVR or SAVR)	9	7	9	7	9	9	9	9	9	9	9	8	7	9	9	9	8	9	A
		26. • AVA ≤1.0 cm ² (and indexed AVA ≤0.6 cm ² /m ²)• Low flow• Low gradient• Evidence of a severely calcified valve• Asymptomatic• High or intermediate surgical risk	No Intervention	6	3	3	7	9	1	6	7	6	4	6	7	3	8	7	6	7	6	M
			BAV (bridge to decision)	5	6	3	3	1	3	2	1	2	4	2	2	7	2	3	2	3	3	R

			AVR (TAVR or SAVR)	4	7	9	4	4	8	3	2	3	6	3	4	6	3	3	3	3	4	M
		27. • AVA ≤1.0 cm ² (and indexed AVA ≤0.6 cm ² /m ²)• Low flow• Low gradient• Evidence of a severely calcified valve• Asymptomatic• Low surgical risk	No Intervention	6	3	1	7	9	1	6	7	6	4	6	7	5	7	7	6	7	6	M
			BAV (bridge to decision)	5	5	1	4	1	2	2	1	2	4	2	2	3	1	3	2	3	2	R
			AVR (TAVR or SAVR)	4	6	9	4	4	9	4	3	3	4	4	4	5	3	3	4	3	4	M
		28. • AVA ≤1.0 cm ² (and indexed AVA ≤0.6 cm ² /m ²)• Normal flow• Low gradient• Confirmation of internal consistency of the AVA, flow, and gradient measurements• Evidence of a severely calcified valve• Symptoms believed to be due to AS• High or intermediate surgical risk	No Intervention	2	4	6	4	3	6	3	3	3	4	4	3	3	3	3	3	3	3	R

			BAV (bridge to decision)	4	8	3	4	1	3	4	4	4	4	4	3	7	4	4	4	5	4	M	
			AVR (TAVR or SAVR)	8	6	3	8	7	3	7	7	7	4	6	7	6	7	7	7	7	7	7	A
		29. • AVA ≤1.0 cm ² (and indexed AVA ≤0.6 cm ² /m ²)• Normal flow• Low gradient• Confirmation of internal consistency of the AVA, flow, and gradient measurements• Evidence of a severely calcified valve• Symptoms believed to be due to AS• Low surgical risk	No Intervention	2	4	6	3	1	5	3	2	3	2	4	3	2	3	3	3	3	3	3	R
			BAV (bridge to decision)	4	7	2	3	1	2	3	1	3	4	4	2	7	3	4	3	4	4	3	R
			AVR (TAVR or SAVR)	8	6	5	7	7	4	7	8	7	7	6	8	6	7	7	7	7	9	7	A
Table 3: Severe AS: High or Extreme Risk Patients	Due to Multiple Comorbidities	30. • Severe symptomatic AS• STS PROM 8-15%• Health status seems to be influenced more by comorbidities than AS• Anticipated life expectancy >1 year	No Intervention	4	2	2	5	5	4	4	4	4	5	4	3	5	4	5	4	4	4	4	M

			BAV (as bridge or palliative care)	5	4	3	4	5	2	5	5	3	5	4	4	4	5	5	5	5	5	M
			TAVR	7	8	8	5	5	7	7	7	4	5	7	7	6	7	7	7	8	7	A
			SAVR	4	4	8	5	5	4	4	4	3	5	4	5	4	6	5	4	7	4	M
		31. • Severe symptomatic AS• STS PROM 8-15%• Health status seems to be influenced more by AS than comorbidities• Anticipated life expectancy >1 year	No Intervention	2	2	1	3	1	2	2	2	2	2	2	2	3	2	2	2	2	2	R
			BAV (as bridge or palliative care)	4	4	2	4	3	2	4	4	4	5	4	2	4	4	4	4	5	4	M
			TAVR	8	9	9	7	9	8	8	8	8	7	8	9	6	8	8	8	8	8	A
			SAVR	5	4	9	6	9	5	5	8	5	5	5	7	6	5	5	5	7	5	M
		32. • Severe symptomatic AS• STS PROM 8-15%• Health status seems to be influenced more by comorbidities than AS• Anticipated life expectancy <1 year	No Intervention	8	5	5	7	9	8	8	9	8	8	8	7	7	8	8	8	7	8	A

			BAV (as bridge or palliative care)	5	7	8	5	4	2	5	5	3	5	5	4	6	5	5	5	6	5	M
			TAVR	3	2	6	3	1	2	3	2	3	3	3	5	3	3	3	3	4	3	R
			SAVR	1	1	2	3	1	1	1	1	1	2	1	3	1	1	1	1	3	1	R
		33. • Severe symptomatic AS• STS PROM 8-15%• Health status seems to be influenced more by AS than comorbidities• Anticipated life expectancy <1 year	No Intervention	6	3	1	5	4	6	6	6	7	5	6	5	4	5	7	6	6	6	M
			BAV (as bridge or palliative care)	6	8	4	5	4	2	6	5	6	4	6	4	4	5	5	6	6	5	M
			TAVR	4	2	9	5	4	3	4	3	3	5	4	7	3	4	3	4	6	4	M
			SAVR	2	1	9	4	4	2	2	2	2	5	3	5	3	2	2	2	3	2	R
		34. • Severe symptomatic AS• STS PROM >15%• Health status seems to be influenced more by comorbidities than AS• Anticipated life expectancy >1 year	No Intervention	6	6	6	7	4	4	6	7	6	5	6	6	4	5	5	6	5	6	M

			TAVR	3	4	2	3	3	1	3	3	3	5	3	5	3	2	3	3	2	3	R	
			SAVR	1	1	1	2	3	1	1	1	1	2	1	2	1	1	1	1	1	1	1	R
		37. • Severe symptomatic AS• STS PROM >15%• Health status seems to be influenced more by AS than comorbidities• Anticipated life expectancy <1 year	No Intervention	7	3	7	7	5	7	7	9	6	5	7	6	7	8	7	7	7	7	7	A
			BAV (as bridge or palliative care)	6	9	6	5	3	2	6	6	6	5	6	4	4	4	5	6	5	5	5	M
			TAVR	3	3	3	4	5	5	3	3	4	5	3	7	6	2	3	3	2	3	R	
			SAVR	1	1	1	3	4	1	1	1	2	2	1	2	1	1	1	1	1	1	1	R
Table 3: Severe AS: High or Extreme Risk Patients	With Frailty or Disability	38. • Severe AS (Vmax 4-4.9 m/s)• Frail• No chest pain or syncope• Fatigue, but no shortness of breath• Normal BNP	No Intervention	5	3	4	7	5	3	5	5	5	5	5	6	5	5	6	5	6	5	6	M
			BAV (as bridge or palliative care)	4	5	5	3	2	2	5	4	4	5	4	4	4	4	3	4	5	4	5	M
			TAVR	6	7	5	4	5	3	5	5	5	5	5	6	6	5	6	5	6	5	6	M
			SAVR	5	3	5	3	4	1	5	3	3	2	3	4	1	3	5	5	6	3	5	R

		39. • Severe AS (Vmax 4-4.9 m/s)• Frail• No chest pain or syncope• Fatigue, but no shortness of breath• BNP elevated	No Intervention	4	3	2	6	5	3	4	4	4	5	4	5	4	4	4	4	4	3	4	M
			BAV (as bridge or palliative care)	4	6	4	4	2	3	4	4	4	5	4	4	4	4	3	4	5	4	5	M
			TAVR	7	7	6	5	7	3	7	6	7	5	7	7	6	7	7	7	7	8	7	A
			SAVR	4	3	4	4	7	3	6	4	3	2	3	5	2	3	4	7	6	4	6	M
		40. • Very severe AS (Vmax ≥5 m/s)• Frail• No chest pain or syncope• Fatigue, but no shortness of breath• Normal BNP	No Intervention	4	3	1	5	5	3	4	4	4	5	4	4	3	4	5	4	5	4	5	M
			BAV (as bridge or palliative care)	4	6	4	3	2	2	5	5	5	5	5	4	4	5	3	5	5	5	5	M
			TAVR	7	7	8	4	5	5	7	7	7	8	7	7	6	7	7	7	7	8	7	A
			SAVR	4	3	8	4	5	1	4	4	3	5	4	3	1	4	5	7	6	4	6	M
		41. • Very severe AS (Vmax ≥5 m/s)• Frail• No chest pain or syncope• Fatigue, but no shortness of breath• BNP elevated	No Intervention	3	2	1	5	5	3	3	3	3	5	3	3	1	3	4	3	3	3	3	R

			BAV (as bridge or palliative care)	4	6	4	4	1	2	4	4	4	5	4	2	3	4	5	4	5	4	M
			TAVR	4	7	7	4	1	5	3	3	4	2	3	5	6	3	3	3	8	4	M
			SAVR	3	2	3	3	1	2	2	2	2	2	2	2	2	2	2	2	3	2	R
Table 3: Severe AS: High or Extreme Risk Patients	Due to Anatomy	44. • Severe symptomatic AS• Porcelain aorta or hostile chest• Otherwise high or intermediate surgical risk due to comorbidities	No Intervention	2	1	1	3	1	2	2	2	3	2	2	1	3	2	2	2	2	2	R
			BAV (as bridge or palliative care)	4	3	4	3	1	3	4	3	4	5	4	4	3	4	2	4	4	4	M
			TAVR	8	9	9	8	9	8	8	8	8	8	8	8	8	8	8	8	8	8	A
			SAVR	3	2	3	3	5	3	3	4	3	5	3	4	1	2	3	3	3	3	R
		45. • Severe symptomatic AS• Porcelain aorta or hostile chest• Otherwise low surgical risk due to comorbidities	No Intervention	1	1	1	3	1	2	1	1	1	2	1	1	2	1	2	1	1	1	R
			BAV (as bridge or palliative care)	3	3	1	3	1	3	3	2	2	2	3	4	3	3	2	3	3	3	R
			TAVR	8	9	9	8	9	8	8	8	7	8	8	8	8	9	8	8	8	8	A
			SAVR	4	2	3	4	6	6	4	5	6	8	4	5	4	4	5	4	6	4	M

Table 3: Severe AS: High or Extreme Risk Patients	Due to Specific Comor- bidities	46. • Severe AS• Oxygen dependent lung disease• Shortness of breath• BNP normal	No Intervention	5	2	2	7	5	5	5	5	3	5	5	6	4	5	5	5	6	5	M
			BAV (as bridge or palliative care)	5	5	4	5	5	3	5	5	5	5	5	4	3	5	5	5	5	5	M
			TAVR	7	7	8	4	5	7	7	7	7	8	7	6	5	7	5	7	6	7	A
			SAVR	3	2	7	3	5	3	3	3	6	5	3	4	1	3	2	4	5	3	R
		47. • Severe AS• Oxygen dependent lung disease• Shortness of breath• BNP elevated	No Intervention	3	1	2	6	5	3	3	3	3	2	3	4	4	3	3	3	3	3	R
			BAV (as bridge or palliative care)	5	7	4	5	5	3	5	5	5	5	5	4	3	5	5	5	6	5	M
			TAVR	8	7	9	5	7	8	8	8	8	8	8	7	7	8	7	8	8	8	A
			SAVR	3	1	7	4	7	6	3	4	6	5	3	4	1	3	3	5	6	4	M
		48. • Severe symptomatic AS• End-stage renal disease• Longstanding dialysis, not a renal transplant candidate• Multiple co- morbidities• STS PROM >15%	No Intervention	5	3	4	5	9	5	5	3	5	5	5	2	5	6	5	5	5	5	M

			BAV (as bridge or palliative care)	4	7	7	4	1	3	4	3	4	5	4	4	1	4	5	4	5	4	M
			TAVR	6	7	8	4	9	7	6	7	6	5	6	8	6	6	5	6	8	6	M
			SAVR	2	2	2	2	9	2	2	7	2	2	2	3	2	2	3	2	3	2	R
		49. • Severe symptomatic AS • End-stage renal disease • Short time on dialysis • Renal transplant candidate • Non-diabetic, non-hypertensive etiology	No Intervention	3	1	1	5	1	3	3	3	3	2	3	3	2	3	3	3	3	3	R
			BAV (as bridge or palliative care)	3	6	4	4	1	3	3	3	3	2	3	4	2	3	3	3	3	4	R
			TAVR	7	8	8	6	9	7	7	7	7	8	7	8	7	8	7	7	7	8	A
			SAVR	7	2	8	4	9	7	7	7	7	8	7	5	5	7	7	7	7	7	A
		50. • Severe symptomatic AS • Cirrhosis with MELD >14	No Intervention	5	2	4	5	9	4	5	5	4	5	5	3	6	5	5	5	5	7	M
			BAV (as bridge or palliative care)	5	4	4	4	1	2	5	5	4	5	5	4	3	5	5	5	5	5	M
			TAVR	7	7	6	5	1	7	7	7	7	8	7	8	6	7	7	7	7	6	A
			SAVR	2	2	4	3	1	6	2	2	1	2	2	6	3	2	3	2	2	2	R
		51. • Severe symptomatic AS • Cirrhosis with MELD <10	No Intervention	3	1	2	3	9	3	3	3	3	2	3	2	3	3	3	3	3	3	R

			BAV (as bridge or palliative care)	4	5	4	3	1	3	4	4	4	5	4	3	3	4	5	4	5	4	M
			TAVR	7	8	9	7	6	8	7	7	7	8	7	8	7	8	7	7	8	7	A
			SAVR	5	4	4	5	6	6	6	7	4	5	6	6	4	7	5	6	5	5	M
		52. • Severe symptomatic AS• Moderate to severe dementia (minimally oriented)• Symptoms described by family but not verbalized by the patient	No Intervention	8	6	4	7	9	8	8	7	8	8	8	6	8	8	7	8	7	8	A
			BAV (as bridge or palliative care)	3	8	5	4	1	1	3	3	3	2	3	4	3	3	3	3	3	3	R
			TAVR	2	4	5	4	1	2	2	2	2	2	2	3	4	1	2	2	2	2	R
			SAVR	1	1	2	3	1	1	1	1	1	2	1	1	1	1	1	1	1	1	R
		53. • Severe symptomatic AS• Malignancy• Life expectancy >1 year	No Intervention	5	1	1	5	9	4	5	5	5	5	5	2	4	5	4	5	5	5	M
			BAV (as bridge or palliative care)	4	3	4	2	1	3	4	4	4	5	4	4	4	4	5	4	5	4	M
			TAVR	7	7	9	7	6	7	7	7	7	8	8	9	6	8	7	7	8	7	A
			SAVR	5	4	5	5	6	6	6	6	5	5	6	6	4	7	5	7	6	6	M

		54. • Severe symptomatic AS• Malignancy• Life expectancy <1 year	No Intervention	8	4	5	7	9	7	7	8	7	2	7	6	7	7	7	7	7	7	A
			BAV (as bridge or palliative care)	5	7	7	4	1	3	5	5	5	5	5	3	4	5	5	5	4	5	M
			TAVR	2	3	4	5	1	2	2	2	2	2	3	5	4	2	3	2	3	2	R
			SAVR	1	1	1	3	1	1	1	1	1	2	1	2	1	1	1	1	1	1	R
Table 4: Symptomatic, High Gradient, Severe AS with associated Coronary Artery Disease		55. • 1 or 2 vessel CAD, no proximal LAD involvement• High or intermediate surgical risk	TAVR	6	5	7	4	9	7	7	8	7	4	7	6	5	7	7	7	3	7	A
			TAVR + PCI	7	6	7	7	9	8	7	8	7	8	8	7	6	7	7	7	8	7	A
			SAVR	6	5	4	4	9	8	4	3	4	2	4	2	3	4	6	4	3	4	M
			SAVR + PCI	7	4	4	3	1	2	4	4	4	2	7	1	3	4	6	4	5	4	M
			SAVR + CABG	3	7	7	6	9	8	7	8	7	8	7	2	6	7	7	7	9	7	A
		56. • 1 or 2 vessel CAD, no proximal LAD involvement• Low surgical risk	TAVR	4	4	4	3	1	7	3	1	3	6	3	7	5	2	3	3	1	3	R
			TAVR + PCI	5	5	4	4	1	7	3	1	3	6	3	7	6	2	3	3	1	3	R
			SAVR	6	5	8	3	9	7	6	3	6	5	6	2	3	6	3	6	3	6	M

			SAVR + PCI	8	5	6	4	1	7	5	3	5	4	7	5	3	5	6	5	5	5	M
			SAVR + CABG	4	8	2	7	9	7	9	9	9	8	9	8	6	9	8	9	9	8	A
		57. • 1 or 2 vessel CAD, including proximal LAD• High or intermediate surgical risk	TAVR	3	4	6	3	1	4	4	6	4	5	4	2	1	4	5	4	1	4	M
			TAVR + PCI	7	5	8	4	7	7	8	8	5	5	8	8	5	8	7	8	8	7	A
			SAVR	3	5	2	3	1	6	3	3	3	2	3	2	1	3	3	3	1	3	R
			SAVR + PCI	7	7	4	4	1	7	3	4	3	5	6	4	1	3	6	3	3	4	M
			SAVR + CABG	9	7	7	6	9	8	7	8	7	9	7	5	7	7	7	7	9	7	A
		58. • 1 or 2 vessel CAD, including proximal LAD• Low surgical risk	TAVR	3	4	3	2	1	4	2	1	2	2	2	1	1	2	3	2	1	2	R
			TAVR + PCI	4	6	3	3	1	7	3	1	3	2	3	5	5	2	3	3	2	3	R
			SAVR	3	3	6	3	1	3	3	1	3	2	3	1	1	3	3	3	1	3	R
			SAVR + PCI	7	3	6	4	1	7	3	2	3	4	6	5	1	3	6	3	3	3	R
			SAVR + CABG	8	8	9	8	9	7	9	9	9	9	9	9	7	9	8	9	9	9	A
		59. • 3 vessel disease; SYNTAX < 22• High or intermediate surgical risk	TAVR	6	4	4	3	1	1	4	6	4	2	4	5	2	4	7	4	1	4	M
			TAVR + PCI	7	4	6	4	7	6	7	8	7	5	7	8	4	7	7	7	8	7	A

			SAVR	3	2	4	3	1	3	3	3	3	2	3	1	1	3	6	3	1	3	R
			SAVR + PCI	7	4	4	4	1	6	3	6	3	2	4	5	1	3	6	3	3	4	M
			SAVR + CABG	9	8	8	7	9	7	7	7	7	8	7	6	7	7	7	7	9	7	A
		60. • 3 vessel disease; SYNTAX < 22• Low surgical risk	TAVR	3	3	2	2	1	1	2	1	2	2	2	2	1	2	3	2	1	2	R
			TAVR + PCI	5	4	2	2	1	6	3	2	3	2	3	5	4	2	3	3	1	3	R
			SAVR	3	3	2	2	1	3	2	1	2	2	2	3	1	2	3	2	1	2	R
			SAVR + PCI	7	4	5	2	1	6	4	4	4	2	5	4	2	3	6	4	1	4	M
			SAVR + CABG	9	8	9	8	9	9	9	9	9	8	9	9	7	9	8	9	9	9	A
		61. • 3 vessel disease; SYNTAX ≥ 22• High or intermediate surgical risk	TAVR	6	2	4	2	1	1	4	5	3	3	4	3	3	3	5	4	1	3	R
			TAVR + PCI	8	2	4	4	7	6	6	7	6	6	6	8	5	6	5	6	8	6	M
			SAVR	3	3	6	3	1	3	2	3	3	3	3	3	1	2	3	3	1	3	R
			SAVR + PCI	6	4	4	4	1	6	4	4	4	3	4	4	2	2	6	4	3	4	M
			SAVR + CABG	7	9	8	6	9	7	7	8	5	8	8	7	6	7	7	8	9	7	A
		62. • 3 vessel disease; SYNTAX ≥ 22• Low surgical risk	TAVR	3	1	1	2	1	1	1	1	1	2	1	2	1	1	3	1	1	1	R
			TAVR + PCI	3	2	2	2	1	6	2	2	2	2	2	4	3	2	3	2	1	2	R
			SAVR	3	2	3	3	1	3	2	1	3	2	2	2	1	1	3	3	1	2	R

			SAVR + PCI	8	4	2	3	1	6	3	2	3	2	4	5	2	2	5	3	1	3	R	
			SAVR + CABG	9	9	9	8	9	9	9	9	9	8	9	9	7	9	8	9	9	9	9	A
		63. • Left main; SYNTAX < 33• High or intermediate surgical risk	TAVR	3	3	2	3	1	2	2	3	2	2	3	1	1	2	5	2	1	2	R	
			TAVR + PCI	6	5	6	4	7	6	7	7	7	5	7	7	3	4	7	7	8	7	A	
			SAVR	3	3	3	3	1	2	2	2	2	2	2	1	1	2	3	2	1	2	R	
			SAVR + PCI	5	3	4	4	1	6	3	3	3	2	4	6	1	3	3	3	3	3	R	
			SAVR + CABG	7	9	8	6	9	7	8	8	8	8	8	7	7	8	7	8	9	8	A	
		64. • Left main; SYNTAX < 33• Low surgical risk	TAVR	3	1	1	2	1	2	1	1	1	2	1	1	1	1	3	2	1	1	R	
			TAVR + PCI	4	3	2	3	1	5	2	2	2	2	2	5	3	2	3	2	1	2	R	
			SAVR	3	3	2	2	1	3	1	1	2	2	2	1	1	1	3	2	1	2	R	
			SAVR + PCI	5	3	3	4	1	3	3	3	3	2	3	6	1	2	3	3	3	3	R	
			SAVR + CABG	9	9	9	8	9	8	9	9	9	9	9	9	7	9	8	9	9	9	A	
		65. • Left main; SYNTAX ≥ 33• High or intermediate surgical risk	TAVR	3	1	3	2	1	1	3	3	3	2	3	1	1	1	5	3	1	2	R	
			TAVR + PCI	5	4	6	4	7	3	6	5	6	6	6	7	2	2	5	6	8	6	M	
			SAVR	3	2	2	3	1	3	1	2	2	2	2	1	1	1	3	2	1	2	R	
			SAVR + PCI	5	3	4	4	1	1	3	3	4	2	4	6	1	3	3	4	3	3	R	

			SAVR + CABG	9	9	8	6	9	8	7	8	8	8	7	8	7	8	7	7	9	8	A
		66. • Left main; SYNTAX ≥ 33• Low surgical risk	TAVR	3	1	2	2	1	1	1	1	1	2	1	1	1	1	3	1	1	1	R
			TAVR + PCI	6	3	2	3	1	1	2	1	2	2	2	3	2	2	3	2	1	2	R
			SAVR	3	2	2	3	1	1	1	1	1	2	1	1	1	1	3	1	1	1	R
			SAVR + PCI	6	3	2	4	1	1	1	1	2	2	3	3	1	1	3	2	1	2	R
			SAVR + CABG	9	9	9	8	9	9	9	9	9	9	9	9	7	9	8	9	9	9	A
Table 5: Severe Symptomatic AS and Other Valve or Ascending Aortic Pathology	Symptomatic AS and Mitral Valve Disease	67. • Severe symptomatic AS• Severe primary MR• High surgical risk	BAV as bridge to decision	6	8	5	3	3	1	4	5	4	4	4	4	6	4	3	4	2	4	M
			TAVR alone	5	4	8	4	9	1	4	4	5	4	5	6	4	4	5	4	5	4	M
			TAVR + PBMV	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
			TAVR + MitraClip	6	9	6	5	9	8	6	6	6	6	6	8	7	6	5	6	8	6	M
			SAVR alone	4	2	5	3	1	3	3	3	3	3	3	1	1	3	2	3	2	3	R
			SAVR + other valve or ascending aortic surgery or myectomy	7	8	8	6	9	7	7	7	7	8	7	5	7	7	7	7	9	7	A

		68. • Severe symptomatic AS• Severe primary MR• Intermediate surgical risk	BAV as bridge to decision	4	6	5	3	1	1	1	3	2	1	2	3	6	1	3	2	1	2	R
			TAVR alone	4	3	6	4	9	1	2	4	3	2	3	4	4	1	3	3	2	3	R
			TAVR + PBMV	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
			TAVR + MitraClip	5	7	5	5	3	8	3	3	3	3	3	8	6	3	3	3	4	3	R
			SAVR alone	3	1	4	3	1	3	3	3	3	3	3	1	1	3	2	3	1	3	R
			SAVR + other valve or ascending aortic surgery or myectomy	7	9	8	7	9	9	8	8	8	8	8	7	7	9	8	8	9	8	A
		69. • Severe symptomatic AS• Severe primary MR• Low surgical risk	BAV as bridge to decision	3	2	1	2	1	1	1	1	1	1	1	2	3	1	2	1	1	1	R
			TAVR alone	3	2	1	2	1	1	1	1	1	1	1	2	3	1	2	1	1	1	R
			TAVR + PBMV	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
			TAVR + MitraClip	3	4	3	3	1	8	2	1	2	1	2	4	6	1	3	2	1	2	R
			SAVR alone	2	1	4	3	1	3	2	1	2	1	2	1	1	1	2	2	1	2	R

			TAVR + MitraClip	4	7	6	5	1	4	3	4	3	4	3	7	6	3	3	3	2	4	M
			SAVR alone	6	2	7	5	9	3	3	2	3	4	3	5	1	3	4	3	1	3	R
			SAVR + other valve or ascending aortic surgery or myectomy	7	9	8	6	9	8	8	8	8	8	8	7	8	8	8	8	9	8	A
		72. • Severe symptomatic AS• Severe secondary MR• Low surgical risk	BAV as bridge to decision	4	2	1	2	1	1	1	1	1	1	1	3	2	1	2	1	2	1	R
			TAVR alone	4	1	1	3	1	3	1	1	1	1	1	4	2	1	2	1	1	1	R
			TAVR + PBMV	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
			TAVR + MitraClip	3	5	1	3	1	4	2	1	2	1	2	5	3	1	2	2	1	2	R
			SAVR alone	4	1	7	4	9	3	3	1	3	1	2	5	1	3	4	3	1	3	R
			SAVR + other valve or ascending aortic surgery or myectomy	9	9	9	7	9	8	9	9	9	9	9	7	6	8	9	9	9	9	A

		73. • Severe symptomatic AS• Severe rheumatic MS (no absolute contraindications to mitral balloon valvuloplasty)• High surgical risk	BAV as bridge to decision	4	8	5	2	3	1	4	4	4	3	2	2	1	4	3	4	5	4	M
			TAVR alone	4	1	6	3	9	5	4	4	4	5	3	2	3	4	5	4	4	4	M
			TAVR + PBMV	7	6	8	7	9	8	7	7	6	5	7	8	6	7	7	7	7	7	A
			TAVR + MitraClip	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
			SAVR alone	4	1	4	3	1	4	2	3	3	5	2	1	1	2	3	3	1	3	R
			SAVR + other valve or ascending aortic surgery or myectomy	7	9	7	6	9	8	7	6	7	7	7	4	7	7	7	7	7	8	A
		74. • Severe symptomatic AS• Severe calcific MS or severe rheumatic MS (with absolute contraindications to mitral balloon valvuloplasty) with extensive mitral annular calcification• High surgical risk	BAV as bridge to decision	4	2	5	3	5	3	4	4	4	5	4	4	2	4	5	4	5	4	M
			TAVR alone	7	4	4	4	9	5	5	5	5	5	6	1	4	5	5	5	5	2	M

			TAVR + PBMV	3	4	7	1	1	1	2	1	2	1	2	4	1	2	1	2	5	2	R
			TAVR + MitraClip	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
			SAVR alone	7	2	3	4	1	3	3	3	3	4	3	1	3	3	5	3	1	3	R
			SAVR + other valve or ascending aortic surgery or myectomy	5	7	7	7	9	7	7	7	7	8	7	6	7	7	7	7	8	7	A
Table 5: Severe Symptomatic AS and Other Valve or Ascending Aortic Pathology	Symptomatic AS and Tricuspid Valve Disease	75. • Severe symptomatic AS• Severe secondary TR• Dilated right ventricle and/or tricuspid valve annulus ≥ 40mm• Minimal to no right ventricular dysfunction• Minimal pulmonary hypertension• Intermediate surgical risk	BAV as bridge to decision	1	5	3	2	5	1	3	1	2	2	2	2	3	2	3	2	5	2	R
			TAVR alone	7	3	7	6	7	6	5	4	5	2	5	6	6	5	3	5	3	5	M
			TAVR + PBMV	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
			TAVR + MitraClip	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
			SAVR alone	6	5	7	3	7	6	3	3	3	3	3	3	4	3	3	3	1	3	R

			SAVR + other valve or ascending aortic surgery or myectomy	6	9	6	7	7	8	8	8	8	8	8	8	8	8	8	8	9	8	A
		76. • Severe symptomatic AS• Severe secondary TR• Dilated right ventricle and/or tricuspid valve annulus ≥ 40mm• Moderate to severe right ventricular dysfunction• Minimal pulmonary hypertension• Intermediate surgical risk	BAV as bridge to decision	1	5	3	2	5	1	2	1	2	2	2	2	3	2	3	2	5	2	R
			TAVR alone	7	4	7	5	7	6	5	4	5	5	5	4	5	5	3	5	6	5	M
			TAVR + PBMV	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
			TAVR + MitraClip	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
			SAVR alone	3	4	7	3	7	7	3	4	3	3	3	2	2	3	3	3	1	3	R
			SAVR + other valve or ascending aortic surgery or myectomy	6	7	7	8	7	9	7	7	7	8	7	8	7	7	7	7	9	7	A

		77. • Severe symptomatic AS• Severe secondary TR• Dilated right ventricle and/or tricuspid valve annulus ≥ 40mm• Moderate to severe right ventricular dysfunction• Severe pulmonary hypertension• High surgical risk	BAV as bridge to decision	4	4	4	4	5	1	4	5	4	5	4	2	5	4	5	4	5	4	M	
			TAVR alone	8	7	7	7	7	6	7	7	7	6	7	6	6	7	7	7	7	7	7	A
			TAVR + PBMV	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
			TAVR + MitraClip	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
			SAVR alone	4	3	2	5	7	7	2	3	2	3	2	2	1	2	3	2	1	2	R	
			SAVR + other valve or ascending aortic surgery or myectomy	6	3	3	6	7	8	5	5	5	5	5	6	6	5	7	5	9	5	M	

			SAVR alone	3	2	1	5	4	3	3	4	3	3	3	2	3	3	3	3	5	3	R
			SAVR + other valve or ascending aortic surgery or myectomy	8	7	9	6	7	9	7	8	7	8	8	7	8	8	7	8	9	8	A
		80. • Severe symptomatic AS• Bicuspid aortic valve• Intermediate surgical risk• Ascending aorta < 4.5cm	BAV as bridge to decision	3	2	3	2	1	1	2	1	2	1	1	2	1	1	3	1	1	1	R
			TAVR alone	7	2	7	3	1	7	4	2	4	3	3	6	5	3	3	3	2	3	R
			TAVR + PBMV	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
			TAVR + MitraClip	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
			SAVR alone	7	9	9	7	7	8	7	8	8	6	6	9	7	7	5	5	8	7	A
			SAVR + other valve or ascending aortic surgery or myectomy	3	5	2	5	7	7	5	2	3	8	7	3	3	5	7	6	9	5	M

		81. • Severe symptomatic AS• Bicuspid aortic valve• Intermediate surgical risk• Ascending aorta ≥ 4.5cm	BAV as bridge to decision	3	1	3	2	1	1	2	1	2	1	1	2	1	1	3	1	1	1	R
			TAVR alone	3	1	1	3	1	4	3	2	3	1	1	3	2	3	3	1	2	2	R
			TAVR + PBMV	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
			TAVR + MitraClip	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
			SAVR alone	3	2	1	4	7	1	4	3	3	6	2	1	3	6	3	2	3	3	R
			SAVR + other valve or ascending aortic surgery or myectomy	8	9	9	7	7	9	7	8	8	8	9	9	8	9	8	9	9	8	A
		82. • Severe symptomatic AS• Bicuspid aortic valve• Low surgical risk• Ascending aorta < 4.5cm	BAV as bridge to decision	2	1	1	1	1	1	1	1	2	1	1	1	1	1	2	1	1	1	R
			TAVR alone	4	1	3	2	1	7	1	1	2	1	1	6	3	1	2	1	2	2	R
			TAVR + PBMV	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
			TAVR + MitraClip	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
			SAVR alone	9	9	9	7	4	8	7	8	9	5	7	9	8	8	5	7	8	8	A

			SAVR + other valve or ascending aortic surgery or myectomy	3	5	3	5	7	6	5	2	3	8	6	2	2	6	8	6	9	5	M	
		83. • Severe symptomatic AS• Bicuspid aortic valve• Low surgical risk• Ascending aorta ≥ 4.5 cm	BAV as bridge to decision	1	1	1	1	1	1	1	1	2	1	1	1	1	1	2	1	1	1	1	
			TAVR alone	2	1	1	2	1	1	2	1	2	1	1	4	3	1	2	1	2	1	2	
			TAVR + PBMV	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
			TAVR + MitraClip	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
			SAVR alone	3	1	1	6	7	1	5	1	2	3	1	2	2	1	3	1	3	2	R	
			SAVR + other valve or ascending aortic surgery or myectomy	8	9	9	7	7	9	8	9	9	8	9	9	8	9	9	9	9	9	9	9

Table 5: Severe Symptomatic AS and Other Valve or Ascending Aortic Pathology	Symptomatic AS and Basal Septal Hypertrophy, Flow Acceleration, and Narrowed LVOT	84. • Symptomatic severe AS• Prominent basal septal hypertrophy with flow acceleration and narrowing in the LVOT• High or intermediate surgical risk	BAV as bridge to decision	4	5	5	1	3	1	3	4	3	3	3	5	4	3	3	3	5	3	R
			TAVR alone	6	5	8	4	7	6	6	7	4	6	6	5	5	6	5	6	7	6	M
			TAVR + PBMV	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
			TAVR + MitraClip	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
			SAVR alone	4	5	6	5	3	7	4	6	4	4	4	5	2	4	3	4	8	4	M
			SAVR + other valve or ascending aortic surgery or myectomy	5	9	8	6	7	9	7	7	7	8	7	7	7	7	7	7	8	7	A
		85. • Symptomatic severe AS• Prominent basal septal hypertrophy with flow acceleration and narrowing in the LVOT• Low surgical risk	BAV as bridge to decision	3	1	1	2	1	1	1	1	1	1	1	2	2	1	2	1	4	1	R

		88. • Asymptomatic severe/critical AS• Elective major surgery• Non obstructive CAD• No signs of cardiac decompensation	No Intervention	3	3	4	7	9	4	4	2	4	2	5	7	1	4	3	5	5	4	M
			BAV	6	5	3	2	1	4	3	1	3	2	2	2	4	3	3	3	5	3	R
			AVR (TAVR or SAVR)	5	7	7	3	9	6	7	7	7	8	7	4	7	7	7	6	9	7	A
		89. • Asymptomatic severe/critical AS• Urgent major surgery• Non obstructive CAD• No signs of cardiac decompensation	No Intervention	5	1	5	7	9	2	5	3	5	2	5	8	3	5	5	5	5	5	M
			BAV	4	8	4	3	1	5	4	5	4	5	4	4	6	4	5	4	5	4	M
			AVR (TAVR or SAVR)	1	2	5	3	1	4	5	7	5	8	5	4	6	5	7	5	7	5	M
Table 7: Failing Aortic Valve Bioprostheses		90. • Severe symptomatic AS or AR• Degenerative surgical bioprosthesis – size ≥23mm• High surgical risk	BAV	4	1	1	1	1	1	1	1	1	2	1	1	1	1	2	1	1	1	R
			TAVR	8	9	9	8	9	9	8	8	8	7	8	8	7	8	8	8	8	8	A
			SAVR	7	5	7	5	9	7	7	6	7	7	6	6	6	7	7	6	9	7	A

		91. • Severe symptomatic AS or AR• Degenerative surgical bioprosthesis – size ≥23mm• Intermediate surgical risk	BAV	3	1	1	1	1	1	1	1	1	1	1	1	1	1	2	1	1	1	R
			TAVR	8	8	7	7	1	8	7	7	7	5	8	8	4	6	8	7	8	7	A
			SAVR	8	6	8	7	9	7	8	8	8	8	7	7	8	8	7	8	9	8	A
		92. • Severe symptomatic AS or AR• Degenerative surgical bioprosthesis – size 21 mm• High surgical risk	BAV	4	1	1	1	1	1	1	1	1	1	1	1	1	1	2	1	1	1	R
			TAVR	6	5	7	4	9	7	6	6	6	5	6	6	4	6	7	6	8	6	M
			SAVR	5	5	7	6	9	7	7	7	7	7	7	7	7	7	7	7	9	7	A
		93. • Severe symptomatic AS or AR• Degenerative surgical bioprosthesis – size 21 mm• Intermediate surgical risk	BAV	4	1	1	1	1	1	1	1	1	1	1	1	1	1	2	1	1	1	R
			TAVR	6	5	5	4	1	7	5	5	6	3	6	7	3	5	7	6	8	5	M
			SAVR	7	7	8	7	9	8	7	7	8	8	8	6	8	8	7	8	9	8	A

